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Abstract
Background and aims: Breast cancer is one of the most common types of malignancy in women with morbidity and mortality (15.0%) in 
the world. The antitumor activity of azurin protein produced by Pseudomonas aeruginosa has been described before. Mammaglobin-A 
(MAM-A) protein is especially expressed in 40%-80% of breast cancer types and this protein is a very specific molecular marker for 
stimulating the immune system. Accordingly, this study investigated the effects of pBudCE4.1-azurin-MAM-A recombinant vector on the 
induction of the immune system in laboratory mice by the real-time polymerase chain reaction (PCR) method. 
Methods: The pBudCE4.1-azurin-MAM-A recombinant and empty vectors were purchased and then separately transformed into Escherichia 
coli for multiplying. Next, each plasmid was extracted and the accuracy of transformation was confirmed by the PCR. These recombinant 
and empty (control) vectors were separately infused into the thigh muscle of the animals and the healthy group was infused with phosphate-
buffered saline. The infusion sites, blood specimens, as well as the serum of the animals were collected and examined by serological and 
molecular tests. 
Results: Molecular and serological studies showed that the serum and expression levels of IL-2, IL-6, IL-7, and IL-10 in infused mice with 
pBudCE4.1-azurin-MAM-A recombinant vector significantly increased compared to healthy animals and injected mice with an empty 
vector (P < 0.05). 
Conclusion: In general, the findings revealed that the pBudCE4.1-azurin-MAM-A recombinant vector can stimulate the immune system 
of the mouse by an increase in the expression levels of IL-2, IL-6, IL-7, and IL-10. Thus, it would be better to examine the effects of this 
recombinant vector as a DNA vaccine on the prevention and treatment of breast cancer.
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Introduction 
Breast cancer is the fifth leading cause of death with an 
average of 522 000 cases per year worldwide. In addition, 
this type of cancer includes 2% of all cancers and is the 
second most common type in developed countries after 
lung cancer (1,2). One out of every 8 to 10 women have 
breast cancer during their lifetime (3,4). According to the 
limitations of current therapies such as surgery, radiation 
therapy, chemotherapy, hormone therapy, and biological 
therapy, it is very important to find a definitive and 
effective treatment based on molecular methods and DNA 
vaccines (5).
Many bacteria produce toxins, extracellular enzymes, 
and pigments. Further, toxins and bacterial enzymes play 
an important role in their pathogenesis (6,7). Although 
bacterial toxins inhibit protein synthesis, DNA replication, 
and cell wall synthesis in response to adverse conditions, 
the evidence is available regarding their useful applications 
(8). For example, Clostridium and Bacillus toxins have 
many applications in medicine, agriculture, and industry 
(9,10).
Bacterial agents, including enzymes, secondary 
metabolites, derived proteins or peptides, and their toxins 
have an anticancer role in cancer cells (11). For instance, 
some bacterial toxins can destroy tumor cells and can alter 
and control cell cycle processes such as cell proliferation, 
apoptosis, and differentiation at low concentrations 
(12). The most common bacterial toxins used for the 
production of immunotoxins are the diphtheria toxin of 
Corynebacterium diphtheriae and exotoxin A and azurin 
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bacteriocin of Pseudomonas aeruginosa. These bacterial 
toxins cause a decrease in cell growth or cycle and can 
naturally induce apoptosis and cell death.  As a supplement, 
therefore, such toxins can be used to improve the therapeutic 
effects of anticancer drugs (13). Among the important 
bacteria, P. aeruginosa is of great significance because its 
toxins and enzymes have therapeutic aspects. It is a Gram-
negative, facultative anaerobic, rod-shaped, motile, and 
non-sporadic bacterium. Furthermore, P. aeruginosa is an 
opportunistic human pathogen and is particularly involved 
in biofilm formation at the surfaces (14). Moreover, azurin 
bacteriocin is a small water-soluble protein and one of the 
bacterial agents with anti-cancer properties that is secreted 
by P. aeruginosa (15,16). This bacteriocin has cytostatic 
properties, can specifically penetrate into human cancer 
cells, and induces apoptosis but has no apparent activity in 
normal cells (17,18).
Mammaglobin-A (MAM-A) protein is one of the 
antigens that is present on the surface of most breast cancer 
cells and is expressed in more than 80% of breast cancer 
patients. This 10.5 kDa secreted glycoprotein contains 
93 amino acids and is encoded by the SCGB2A2 gene 
(19,20). Additionally, MAM-A protein is a very specific 
molecular marker in breast cancer and a suitable target for 
the immune-based therapy of patients with disseminated 
breast cancer (21).
The application of DNA vaccines (a type of subunit 
vaccine) is a novel tool for immunization against bacterial, 
viral, parasitic, and fungal infections and cancers (5,22). 
The major advantages of DNA vaccines are cheapness, 
safety, as well as the ease of development and production, 
heat resistance, and the long-term safety of their use. 
Similarly, these vaccines are subunit and free of the risk of 
infection transmission and induce humoral and cellular 
responses (23).
The finding of DNA vaccines with anticancer property 
is important because these vaccines have a high potential 
for inducing antitumor immunity without any adverse side 
effects. The role of some bacterial toxins in controlling cell 
growth and proliferation is also remarkable. Accordingly, 
the present study was performed by considering the anti-
cancer property of the azurin protein of P. aeruginosa 
and MAM-A antigen as a candidate for the development 
of the breast cancer vaccine. In this study, the effects of 
pBudCE4.1-azurin-MAM-A recombinant vector on IL-
2, IL-6, IL-7, and IL-10 expressions were evaluated in 
laboratory mice.
Materials and Methods
Preparation of Plasmids
In this research, the recombinant pBudCE4.1-azurin-
MAM-A and empty pBudCE4.1 plasmids were purchased 
from Generay Biotech Company (Ltd., Shanghai, China). 
This recombinant vector contains two different multiple 
cloning sites for the insertion of azurin and MAM-A genes 
separately (Figure 1). The lengths of the applied azurin and 
MAM-A genes in the recombinant plasmid were 1287 and 
1309 bp, respectively.
 
Bacterial transformation 
The lyophilized stock of E. coli NovaBlue strain (Novagen 
Company) was prepared from the Cellular and Molecular 
Research Center of Shahrekord University of Medical 
Sciences. This bacterium was overnight-cultured at 37°C 
by shaking at 200 rpm. The competent cells were prepared 
using CaCl2 and heat shock (42
°C for 90 seconds). Then, 
these cells were used for the separate transformation of 
pBudCE4.1-azurin-MAM-A and pBudCE4.1 vectors. 
Next, the transformed colonies were screened on LB 
agar medium containing 25 µg/mL of zeocin antibiotic. 
The accuracy of transformation was checked by colony-
polymerase chain reaction (PCR).
Plasmid Purification 
The bacterial colonies containing recombinant pBudCE4.1-
azurin-MAM-A and pBudCE4.1 vectors were separately 
cultured in 5 and 250 mL LB media (containing zeocin 
antibiotic) at 37°C for 18 hours in an incubator. The plasmid 
extraction was performed using Miniprep and Maxiprep 
Figure 1. The schematic image of pBudCE4.1-azurin-MAM-A 
recombinant vector .
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YTA plasmid extraction kits (Azma Equipments Company, 
Tehran, Iran). In addition, the purity and concentration of 
the extracted plasmid were measured using a NanoDrop 
spectrophotometer (Thermo Scientific™ NanoDrop 2000, 
Wilmington, DE, USA) in a ratio of absorbance at 260 
nm and 280 nm. The PCR reaction was also performed to 
confirm the accuracy of the extracted plasmid and detect 
the presence of the target genes. 
Amplification of target genes
The specific primers for the azurin and MAM-A (target 
genes) of the recombinant vector were designed using 
Gene Runner software, version 3.05, and the sequences 
of primers and their identity were analyzed in the BLAST 
system of the National Center for Biotechnology (Table 1)
The PCR reaction was performed in 0.2 mL microtubes 
at a final volume of 25 µL. Each reaction contained the 
selected colonies or extracted plasmids (50 ng), the 1X 
PCR buffer, 1 µm of each forward and reverse primers, 0.2 
mm dNTP mix, 2 mm MgCl2, and 1 unit of Taq DNA 
polymerase (all manufactured by CinnaGen Company, 
Tehran, Iran). The negative control consisted of all the 
above-mentioned substances except for the transformed 
colony or the template DNA plasmid. Then, the 
microtubes were inserted into the thermal cycler (Gene 
Atlas G, ASTEC Company, Seoul, Korea) to perform 
the temperature steps of gene replication. Further, PCR 
reaction temperatures included several cycles as one step of 
denaturation at 94°C for 5 minutes, 35 repetitive cycles of 
1 minute of denaturation at 94°C, annealing at 65°C (for 
azurin gene) and 66°C (for MAM-A gene) for 50 seconds, 
as well as the extension step at 72°C for 50 seconds and the 
final extension stage at 72°C for 10 minutes. The amplified 
products were electrophoresed on 1% agarose gel at 110 
V for 45 minutes in the running buffer (TBE 1%). After 
an appropriate ethidium bromide (2 µg/mL) staining, the 
gel was visualized under the UVIDoc gel documentation 
system (Uvitec, UK). 
Animals Grouping and Infusions Program
Twenty-four female BALB/c mice with approximately 18 
g weight were divided into 3 groups (A to C) according 
to Table 2. Groups A, B, and C included infused mice 
with the pBudCE4.1-azurin-MAM-A recombinant vector, 
empty pBudCE4.1 plasmid, and PBS recipient (healthy 
group), respectively. The treatment times were 15 days 
and the period time for inducing the immune system by 
the recombinant vector was set for 15 days after the last 
injection.
 
Sampling
At the end of the treatments, the mice of all groups were 
killed by chloroform via ethical conditions (without 
disturbing the animal). The tissue of the infusion site and 
blood specimens of each animal were collected, followed 
by taking the whole blood samples of each mouse directly 
by the aspiration from the heart of the animal. Then, the 
samples were individually collected in EDTA tubes and 
stored at -70°C for RNA extraction and molecular testing. 
The residues of half of the blood samples (blood clotted) 
were collected in a standard 1.5 mL microtube and then 
were centrifugated and stored at -20°C for serological tests 
(ELISA). The tissue of the injection site (thigh muscle) of 
each animal was isolated separately with a sterile scalpel 
and razor blades and, after RNA extraction and cDNA 
synthesis, was used for investigating the expression of the 
target genes (i.e., azurin and MAM-A) by the real-time 
(RT)-PCR.
Table 1. Details of Primers and Their Sequences
Gene Primers Name Sequences Annealing Temperature (ºC) Product Kength (bp) Accession Number
azurin
Azu-F 5′-ATGCTACGTAAACTCGCTGCC-3′ 65 292
M30389
Azu-R 5′-TGTCGTCGGGCTTCAGGTAATC-3′
MAM-A
Mam-F 5′-CAGCGGCTTCCTTGATCCTTG-3′ 66 221
NM_002411
Mam-R 5′-TGGCATTGTCGTCTATGAACTCTTG-3′
IL-2
IL-2-F 5′-TGCCTAGAAGATGAACTTGGACCTC-3′ 65 229
BC116845
IL-2-R 5′-GGCTTGTTGAGATGATGCTTTGAC-3′
IL-6
IL-6-F 5′-AGAGTCCTTCAGAGAGATACAG-3′ 64 246
M24221
IL-6-R 5′-ACAAACTGATATGCTTAGGC-3′
IL-7
IL-7-F 5′-AGGACATGTAGTAACAACCTCC-3′ 64 220
NM_008371
IL-7-R 5′-ATGATTGCATTACAAAAATCTG-3′
IL-10
IL-10-F 5′-CTGGACAACATACTGCTAACCGACTC-3′ 66 250
NM_010548
IL-10-R 5′-TCTTCACCTGCTCCACTGCCTTG-3′
GAPDH
GAPDH-F 5′-TCCCGTAGACAAAATGGTGAAGG-3′ 65 261
XM_017321385
GAPDH-R 5′-ATGTTAGTGGGGTCTCGCTCCTG-3′
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Expression of genes in tissue and blood samples
RNA extraction was performed on blood and tissue 
samples from the injection site in all treated mice using the 
RNX plus solution (CinnaGen Company, Tehran, Iran) 
according to the manufacturer’s instructions. Then, 1 µg 
of the extracted RNA was synthesized for cDNA according 
to the standard protocol of the cDNA synthesis kit (Yekta 
Tajhiz Azma, Tehran, Iran). Furthermore, the expression 
of the azurin and MAM-A target genes of the recombinant 
vector in the tissue of the injection site was performed by 
the RT-PCR method according to the above-mentioned 
procedure. The amplified products were analyzed on 1% 
agarose gel electrophoresis. 
Moreover, the expression levels of important cytokines 
and immunoglobulins in breast cancer, including IL-2, IL-
6, IL-7, and IL-10 in blood samples from the animals, were 
compared with the normal group by qRT PCR. The details 
of each designed primer are shown in Table 1.
The RT PCR was performed on a Rotor-Gene 6000 
machine (Corbett, Australia). Additionally, each cDNA 
sample was diluted 1 to 5 and the q-PCR reaction mixture 
in a 0.2 mL microtube was prepared in triplicate at a final 
volume of 13 µL (on ice) for each reaction. Each reaction 
consisted of 50 ng of the cDNA sample (1 μL) added to 6.5 
μL of YTA 1X SYBR Green qPCR Mix (Yekta Tajhiz Azma, 
Tehran, Iran), 0.5 μL of each forward and reverse primers 
(2 μM), and 4.5 μL distilled water (dH2O). In addition, the 
non-template control was inserted to evaluate the reaction 
contamination or primers for each step of RT PCR. The 
temperature conditions of RT PCR reaction consisted of a 
single denaturation step at 95°C for 3 minutes, 40 cycles of 
denaturation at 94°C for 30 seconds, primer annealing at 
65°C for 3 minutes, and elongation at 72°C for 30 seconds. 
Finally, the melting curve analysis was performed at the end 
of the reaction. The relative expressions were monitored by 
Rotor-Gene RT analysis software, version 6.0 (Qiagen, 
Inc., Valencia, CA, USA) using the comparative Cts (2−
ΔΔCt) (Livak method). 
ELISA test 
To this end, 40 µL of the serum samples of all mice was 
subjected to determine the serum levels of IL-2, IL-6, IL-
Table 2. Classification of animals and their infusion and treatment schedules
Treatment Program Number of Mice Group
Recombinant vector* infusion (3 times, days 0, 7, and 15) and 15 days after the last injection sampling for serological and 
molecular studies 
8 A
Infused with empty pBudCE4.1vector (without target genes) for 3 times (days 0, 7, and 15) and 15 days after the last injection 
sampling for serological and molecular tests
8 B
Infused with PBS for 3 times (days 0, 7, and 15) and 15 days after the last infusion sampling for serological and molecular 
tests
8 C
Note. *Recombinant vector: pBudCE4.1-azurin-MAM-A. 
7, and IL-10 cytokines using separately enzyme-linked 
immunosorbent assay (ELISA) kits (Hangzhou, Chin 
Hangzhou Eastbiopharm Company, Ltd., Hangzhou, 
China) according to the described method by the company. 
The ELISA sandwich method was used for all tests and 
the samples were finally measured using the Stat Fax–2100 
ELISA plate reader (Awareness Technology, Palm City, FL) 
under 450 nm wavelength.
Statistical analysis 
All experiments were repeated at least three times and data 
were entered and analyzed using the Statistical Package 
for the Social Sciences software (SPSS, Inc., Chicago, IL, 
USA), version 20. Further, the mean differences between 
the groups were calculated by an independent t-test or 
the analysis of variance (ANOVA) statistical methods. All 
graphs were prepared using GraphPad Prism, version 7 
(GraphPad Software, San Diego, CA, USA). In this study, 
a P value of less than 0.05 was considered statistically 
significant.
Results
Verification of Bacterial Transformations
The successful transformation of the pBudCE4.1-azurin-
MAM-A recombinant vector into the bacterial host was 
confirmed by PCR. Furthermore, the amplified fragments 
with lengths of 292 and 221 bp were observed on an agarose 
gel for azurin and MAM-A genes,  respectively (Figure 2). 
Expression of target genes 
The expression of the target genes of the pBudCE4.1-
azurin-MAM-A recombinant vector in the tissue of the 
injection site on the agarose gel showed the DNA bands 
with 292 and 221 bp lengths for azurin and MAM-A 
genes, respectively (Figure 3). These results indicated the 
successful expression of the recombinant vector in the 
infusion site of the animal.
Serological analysis
The evaluation of the serum levels of IL-2, IL-6, IL-
7, and IL-10 by the ELISA test (Figure 4) showed that 
these cytokines in injected mice with the pBudCE4.1-
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azurin-MAM-A recombinant vector (group A) increased 
significantly (P < 0.05) compared to injected mice with the 
pBudCE4.1 empty vector (group B, without target genes) 
and PBS recipient (group C, control).
Quantitation of cytokine gene expression by RT-PCR
As displayed in Figure 5, the expression level of IL-2, IL-
6, IL-7, and IL-10 cytokines in infused animals with a 
recombinant pBudCE4.1-azurin-MAM-A plasmid (group 
A) increased significantly (P < 0.05) compared to injected 
mice with the empty vector (group B, without target gene 
delivery) and PBS (group C as a control) .
Discussion
Nowadays, due to the lack of effective therapy against 
breast cancer and the disadvantages of existing therapies, it 
is important to find new strategies for prevention, therapy, 
and induction of the immune system in the body against 
cancer cells. Due to the anti-cancer effect of the azurin 
protein of P. aeruginosa and the stimulation of the immune 
system by MAM-A protein, the present study investigated 
the immunogenicity of pBudCE4.1-azurin-MAM-A 
recombinant vector (encoded these two genes) in BALB/c 
mice.
According to the similarity of the human MAM-A gene 
sequence to the mouse MAM-A antigen and due to the 
application of this vector as a DNA vaccine in humans in 
the future, this gene was used in the recombinant vector to 
induce the immune system in an animal model.
The successful expression of azurin and MAM-A genes in 
the tissue of the injection site of BALB/c mice was observed 
by RT-PCR reaction. Additionally, the ELISA assay showed 
that IL-2, IL-6, IL-7, and IL-10 serum levels in recipient 
mice with the recombinant pBudCE4.1-azurin-MAM-A 
vector (group A) increased significantly (P<0.05) compared 
to infused mice with empty vector (group B) and PBS 
(group C). Moreover, the RT-PCR findings demonstrated 
that the pBudCE4.1-azurin-MAM-A recombinant vector 
(group A) stimulates the immune system by increasing the 
expression of IL-2, IL-6, IL-7, and IL-10 cytokine genes. 
However, this increase in the expression of these cytokines 
and immune system incitement was not observed in B and 
C groups and control mice. The significant enhancement 
of the expression of these cytokines in recombinant 
vector recipient mice by molecular methods confirmed 
the findings of the ELISA test on the stimulation of the 
immune system of the animals. 
It should be noted that IL-2 is an immunogenic cytokine 
in breast cancer. This cytokine plays an important role in 
the activation of natural killer cells (NK) and monocytes 
and it is a major growth factor for B and T lymphocytes 
(24). In addition, by inducing acute-phase proteins, IL-6 
induces tissue invasion at the tumor site, as well as Th17 10 
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Figure 2. The amplified products of the azurin and MAM-A genes of 
Recombinant Plasmid by PCR on 1% Agarose Gel Electrophoresis
Note. M: 100 bp DNA marker (Yekta Tajhiz Azma, Tehran, Iran); 
Lines 1 and 2: The amplified fragments for the azurin gene; Line 3: 
Negative control (no DNA); Line 4: The MAM-A gene band.
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Figure 3. The expression of azurin and MAM-A genes in the tissue of 
the infusion site of BALB/c mice by the recombinant vector.
Note. M and M1: 1 kb and 100 bp DNA markers, respectively 
(Thermo Fisher Scientific); Lanes 1, 2, 4, and 5: The amplified azurin 
gene in the tissue of infused mice with the recombinant vector; Lane 
3: Injected mice with the pBudCE4.1 empty vector (control group); 
Lane 6: Injected mice with PBS; Lane 7: Negative control (without 
template DNA); Lanes 8, 9, 11, and 12: The amplified fragments 
of the MAM-A gene in the injection site of infused mice by the 
recombinant vector; Lane 10: Injected mouse by the pBudCE4.1 
empty vector; Lane 13: Injected with PBS; Lane 14: Negation control 
(without DNA).
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cells, and thus affects B cells (25). Further, IL-7 induces the 
immune response type 1 increases CD8+ cytotoxicity, and 
stimulates NK cells and lymphokine-activated killer (LAK) 
cells (26,27). Similarly, IL-10 promotes angiogenesis and 
tissue invasion, while it inhibits the growth mechanism 
and metastasis of breast cancer cells (28,29). Thus, the 
expression enhancement of these cytokines in recombinant 
vector recipient mice, which was observed in this study, 
confirms the correct function of this recombinant gene 
construct by the delivery of azurin and MAM-A genes in 
immune system stimulation.
So far, no study has evaluated the synergistic effects of 
the azurin gene of P. aeruginosa with the human MAM-A 
gene as a recombinant gene structure in the stimulation of 
the immune system in laboratory animals. The findings of 
the study by Yamada et al showed that azurin protein in 
nude mice that received human cancer cells leads to the 
regression of human UISO-Mel-2 tumors. Accordingly, 
they suggested that it can be potentially used for cancer 
therapy and the stimulation of the immune system (30). 
However, in our study, the simultaneous effects of bacterial 
azurin and human MAM-A as a gene structure on immune 
system stimulation were examined and the appropriate 
stimulation of cytokines was observed using molecular and 
serological methods. 
In their clinical trial study, Tiriveedhi et al investigated 
the immune and biological effects of the MAM-A 
DNA vaccine against breast cancer. After vaccination, 
their findings represented a significant increase in the 
frequency of CD8+ T cells specific for MAM-A by using 
flow cytometry. There was also a significant increase in the 
number of MAM-A-specific IFNγ-secreting T cells. They 
further indicated that the MAM-A DNA vaccine was safe 
and capable of stimulating and responding to the immune 
system, but also suggested that further studies must be done 
to evaluate the potential of the DNA MAM-A vaccine in 
the prevention or therapy of breast cancer (31). However, 
the present study, to the best of our knowledge, was the first 
one to use MAM-A and azurin genes as gene constructs and 
to determine the efficacy of pBudCE4.1-azurin-MAM-A 
recombinant plasmid by serological (ELISA) and molecular 
(real-time PCR) tests. The results of our study revealed that 
the serum levels and mRNA expression levels of IL-2, IL-6, 
IL-7, and IL-10 cytokines increased significantly in injected 
mice with the recombinant vector (group A) compared to 
lack of the target genes in the group B (injected mice with 
empty vector) and injected with PBS (group C).
In another study, the potential effects of azurin on non-
small cell lung cancer were examined and the anticancer 
effects of this bacterial protein were demonstrated in several 
cancer cell lines, especially breast cancer (32,33). The 
present study investigated the effects of the pBudCE4.1-
azurin-MAM-A recombinant vector via the expression of 
the azurin bacteriocin of P. aeruginosa and human MAM-A 
on the stimulation of the immune system of BALB/c mice 
by molecular and serological methods. The stimulation of 
the mouse immune system was observed by inducing the 
increased expression of cytokines.
In conclusion, the findings of this study showed that 
this recombinant vector via expressing azurin and MAM-A 
genes in BALB/c mice has a potential role in stimulating 
the immune system of the animal by increasing the serum 
levels and the expression of cytokine genes. Thus, other 
studies are suggested to evaluate the effects of this gene 
construct on other experimental animals and cancer cell 
lines. Finally, further research on this recombinant gene 
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Figure 4. Comparison of the serum levels of IL-2, IL-6, IL-7, and IL-
10 cytokines in the mice of each group by the ELISA test.
Note. A: The injected mice with the pBudCE4.1-azurin-MAM-A 
recombinant vector; B: The injected mice with empty pBudCE4.1 
vector (without target genes); C: The injected mice with PBS
Figure 5. Comparison of cytokine gene expression levels in the 
BALB/c mice of each group.
Note. A: The recipient animals with pBudCE4.1-azurin-MAM-A 
recombinant vector;  B: The infused mice with empty pBudCE4.1 
vector (without target genes); C: The PBS-infused mice. 
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construct may promise a new strategy for the prevention 
and treatment of breast cancer in the near future.
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